Intellia says court dismissed securities class action; director pay and patent suits continue

Intellia Therapeutics (Nasdaq: NTLA) said in its 10-Q filed August 6, 2026 that the U.S. District Court for the District of Massachusetts fully granted the defendants' motion to dismiss a securities class action, Gonzalez v. Intellia Therapeutics, Inc., No. 1:25-cv-01353, on June 18, 2026. The plaintiffs did not appeal. The filing also describes two cases that remain open: a Delaware derivative suit over director pay, Aiello v. Bhanji et al., C.A. No. 2025-0543-BWD, and a patent suit, BlueAllele Corp. v. Intellia Therapeutics, Inc., in the District of Delaware.

The defendants in Gonzalez were Intellia and "certain of its officers", whom the 10-Q does not name. In Aiello, the defendants are certain current and former directors, called the Individual Defendants, with Intellia as nominal defendant. BlueAllele sued Intellia itself.

The case

Gonzalez was filed on February 11, 2025 by a purported stockholder on behalf of a putative class that bought Intellia shares from July 30, 2024 through January 8, 2025. The court appointed co-lead plaintiffs on May 26, 2025, and they filed an amended complaint on July 23, 2025. It alleged claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, based on statements about the NTLA-3001 program and the demand for viral-based editing.

Aiello was filed on May 15, 2025 in the Delaware Court of Chancery. The complaint alleges breach of fiduciary duty, unjust enrichment and waste of corporate assets, based among other things on alleged excessive pay to non-employee directors. It seeks unspecified damages and restitution from the Individual Defendants, corporate governance reforms from Intellia, and attorneys' fees.

BlueAllele filed its complaint on July 8, 2024. It alleges that Intellia's experimentation, basic research, identification, optimization, manufacturing and use of bi-directional insertion template technology infringes its patents. It seeks unspecified compensatory damages and an injunction.

Defendants

In Gonzalez, the defendants were Intellia and certain officers. Intellia's proxy statement filed April 30, 2025 says John M. Leonard has been president and chief executive officer since January 2018 and Edward J. Dulac III chief financial officer since July 2024, so both held those posts during the class period. Both signed the 10-K filed February 27, 2025 in those roles. The 10-Q does not say they were defendants.

In Aiello, the 10-Q does not list the Individual Defendants beyond the caption, which leads with Bhanji. That proxy statement listed the board when the suit was filed: Muna Bhanji, Brian Goff and Jesse Goodman as class I directors, Fred Cohen and Frank Verwiel as class II directors, and William Chase, Georgia Keresty and John M. Leonard as class III directors. The caption names Bhanji; the filings do not say which of the others are defendants.

In BlueAllele, the defendant is Intellia Therapeutics, Inc.

Where it stands

In Gonzalez, the defendants moved to dismiss on September 8, 2025, the court held a hearing on January 14, 2026, and it granted the motion on June 18, 2026. The 10-Q does not say whether the dismissal was with or without prejudice.

In Aiello, Intellia and the Individual Defendants filed answers on July 11, 2025 and discovery began. Intellia says it cannot determine the likelihood of an unfavorable outcome or estimate any loss.

In BlueAllele, Intellia moved to dismiss on September 12, 2024. The court denied the motion on December 9, 2024 and discovery began. Intellia answered and filed counterclaims on January 6, 2025. On February 21, 2025 the court substantially denied BlueAllele's motion to dismiss those counterclaims, granting it for one counterclaim. Intellia again says it cannot determine the likelihood of an unfavorable outcome or estimate the loss.

Why it matters to shareholders

Intellia says it records a liability when a loss is probable and can be estimated. For Aiello and BlueAllele, it says it cannot determine the likelihood of an unfavorable outcome or estimate a loss. The 10-Q states that, apart from the items it describes, there were no material changes to outstanding litigation in the quarter, and Intellia was not a party to any material new litigation.

Report an error

Companies in this story

NTLAIntellia Therapeutics, Inc.NASDAQ · United StatesOpen the desk